Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate the safety and effectiveness of VX-548 in treating acute pain.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Suzetrigine (SUZ) | Experimental | Participants received SUZ 100 milligram (mg) as first dose, followed by SUZ 50 mg every 12 hours (q12h) for 14 days or until pain resolves, whichever occurs first. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Suzetrigine | Drug | Tablets for oral administration. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | Day 1 up to Day 30 |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Participants Reporting Good, Very Good, or Excellent on a Patient Global Assessment (PGA) Scale | The PGA is a single-item assessment of patient perceptions of the method of pain control with the study drug and is evaluated on a 5-point Likert scale as: (poor, fair, good, very good or excellent). Percentage of participants who reported good, very good or excellent on the PGA scale was reported. |
Not provided
Key Inclusion Criteria:
Key Exclusion Criteria:
Surgical participants:
History of any illness or any clinical condition that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the participant
Other protocol defined Inclusion/Exclusion criteria may apply.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Anaheim Clinical Trials | Anaheim | California | 92801 | United States | ||
| Trovare Clinical Research | Bakersfield, CA |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 41689837 | Derived | Yuan S, Ji H, Lu Y, Zhang Z, Tang H. The Clinical Application of Suzetrigine. J Pain Palliat Care Pharmacother. 2026 Jun;40(2):311-320. doi: 10.1080/15360288.2026.2624502. Epub 2026 Feb 14. | |
| 40165940 | Derived | McCoun J, Winkle P, Solanki D, Urban J, Bertoch T, Oswald J, Swisher MW, Taber LA, Healey T, Jazic I, Correll DJ, Negulescu PA, Bozic C, Weiner SG; VX-548-107 Study Team. Suzetrigine, a Non-Opioid NaV1.8 Inhibitor With Broad Applicability for Moderate-to-Severe Acute Pain: A Phase 3 Single-Arm Study for Surgical or Non-Surgical Acute Pain. J Pain Res. 2025 Mar 25;18:1569-1576. doi: 10.2147/JPR.S509144. eCollection 2025. |
Not provided
Not provided
Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Suzetrigine (SUZ) | Participants received SUZ 100 milligram (mg) as first dose, followed by SUZ 50 mg every 12 hours (q12h) for 14 days or until pain resolves, whichever occurs first. |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Nov 9, 2022 | Jun 13, 2025 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Day 14 or at Pain Resolution, whichever occurs first |
| Bakersfield |
| California |
| 93301 |
| United States |
| Mart Medical Research Group LLC | Miami | Florida | 33166 | United States |
| Mart Medical Research Group LLC | South Miami | Florida | 33143 | United States |
| Atlanta Center for Medical Research | Atlanta, GA | Atlanta | Georgia | 30331 | United States |
| Cypress Surgery Center | Wichita | Kansas | 67226 | United States |
| OrthoNebraska Hospital | Omaha | Nebraska | 68144 | United States |
| Center for Orthopaedic Reconstruction and Excellence | Jenks | Oklahoma | 74037 | United States |
| HD Research LLC | First Surgical Hospital | Bellaire | Texas | 77401 | United States |
| HD Research LLC | Legent Orthopedic Hospital | Carrollton | Texas | 75006 | United States |
| Renovatio Clinical | Houston | Texas | 77380 | United States |
| Futuro Clinical Trials | McAllen | Texas | 78501 | United States |
| South Texas Spine & Surgical Hospital | San Antonio | Texas | 78258 | United States |
| Wasatch Clinical Research | Salt Lake City | Utah | 84107 | United States |
| Safety Set |
|
| COMPLETED |
|
| NOT COMPLETED |
|
|
Baseline data was analyzed based on the Full Analysis Set (FAS), defined as all participants who received at least 1 dose of study drug.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Suzetrigine (SUZ) | Participants received SUZ 100 mg as first dose, followed by SUZ 50 mg q12h for 14 days or until pain resolves, whichever occurs first. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | years |
| ||||||||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants | No |
| ||||||||||||||||||||||
| Race/Ethnicity, Customized | Count of Participants | Participants | No |
| ||||||||||||||||||||||
| Race/Ethnicity, Customized | Count of Participants | Participants | No |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | Safety Set included all participants who received at least 1 dose of study drug. | Posted | Count of Participants | Participants | No | Day 1 up to Day 30 |
|
|
| |||||||||||||||||||||||||||||||||
| Secondary | Percentage of Participants Reporting Good, Very Good, or Excellent on a Patient Global Assessment (PGA) Scale | The PGA is a single-item assessment of patient perceptions of the method of pain control with the study drug and is evaluated on a 5-point Likert scale as: (poor, fair, good, very good or excellent). Percentage of participants who reported good, very good or excellent on the PGA scale was reported. | Full Analysis Set (FAS) included all participants who received at least 1 dose of study drug. | Posted | Number | percentage of participants | Day 14 or at Pain Resolution, whichever occurs first |
|
|
Day 1 up to Day 30
Safety Set included all participants who received at least 1 dose of study drug.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Suzetrigine (SUZ) | Participants received SUZ 100 mg as first dose, followed by SUZ 50 mg q12h for 14 days or until pain resolves, whichever occurs first. | 0 | 256 | 2 | 256 | 18 | 256 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Cellulitis | Infections and infestations | MedDRA 26.1 | Systematic Assessment |
| |
| Suicidal ideation | Psychiatric disorders | MedDRA 26.1 | Systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Headache | Nervous system disorders | MedDRA 26.1 | Systematic Assessment |
|
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Medical Monitor | Vertex Pharmaceuticals Incorporated | 617-341-6777 | medicalinfo@vrtx.com |
| Prot_000.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Dec 20, 2023 | Jun 13, 2025 | SAP_001.pdf |
| ID | Term |
|---|---|
| D010146 | Pain |
| ID | Term |
|---|---|
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| Asian |
|
| American Indian or Alaska Native |
|
| Native Hawaiian or other Pacific Islander |
|
| Multiracial |
|
|